Want to see ABSI full AI Analyst Report?
ABSI Stock Chart & Stats
$9.63
$0.18(2.38%)
At close: 4:00 PM EDT
$9.63
$0.18(2.38%)
Day’s Range― - ―
52-Week Range$2.24 - $12.06
Previous CloseN/A
Volume400.70K
Average Volume (3M)4.08M
Market Cap
$1.56B
Enterprise Value$1.63B
Total Cash (Recent Filing)$201.14M
Total Debt (Recent Filing)$3.68M
Price to Earnings (P/E)―
Beta2.41
Next Earnings
Nov 12, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding171,614,010
10 Day Avg. Volume3,981,907
30 Day Avg. Volume4,079,662
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)2.52
Price to Sales (P/S)170.48
P/FCF Ratio-5.08
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue1.04K
Enterprise Value/Gross Profit-407.46
Enterprise Value/Ebitda-14.81
Forecast
1Y Price Target
$14.63Price Target Upside51.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.8
Revenue Forecast (FY)$3.89M
Bulls Say, Bears Say
Bulls Say
Extended Cash RunwayThe strengthened cash position gives AbSci substantial time to advance its clinical programs and platform without immediate financing pressure. The extended runway supports execution through important 2026–2027 milestones and reduces near-term solvency risk despite ongoing operating losses.
AI-Enabled Discovery EfficiencyReported improvements in Origin’s library efficiency could lower the resources required to identify viable biologic leads and accelerate progression toward IND-enabling work. If reproducible across programs, this integrated AI and wet-lab capability may improve development productivity.
Promising ABS-201 PharmacokineticsA long estimated half-life and favorable early tolerability support a potentially convenient dosing schedule for ABS-201. These findings strengthen the program’s development rationale and could improve its commercial profile, although efficacy and durability still require confirmation.
Bears Say
Minimal Revenue And Deep LossesAbSci has not yet demonstrated meaningful commercial scale: revenue remains very small and declining while losses are substantial. This gap indicates that the current cost base is far ahead of monetization, leaving future financial performance dependent on successful development and partnerships.
Clinical Efficacy UnprovenThe encouraging safety and pharmacokinetic observations do not yet establish that ABS-201 produces meaningful hair regrowth or other clinical benefits. Until unblinded and longer-duration results are available, the program’s development value and commercial prospects remain materially uncertain.
Execution And Commercialization RiskAlthough Lilly’s involvement provides support and external validation, AbSci remains responsible for advancing and commercializing ABS-201. Retaining program ownership preserves potential upside but also leaves clinical execution, future funding needs, and commercialization outcomes principally with the company.
AbSci News
ABSI FAQ
What was AbSci’s price range in the past 12 months?
AbSci lowest stock price was $2.24 and its highest was $12.05 in the past 12 months.
What is AbSci’s market cap?
AbSci’s market cap is $1.56B.
When is AbSci’s upcoming earnings report date?
AbSci’s upcoming earnings report date is Nov 12, 2026 which is in 20 days.
How were AbSci’s earnings last quarter?
AbSci released its earnings results on Aug 11, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.191 by -$0.019.
Is AbSci overvalued?
According to Wall Street analysts AbSci’s price is currently Undervalued.
Does AbSci pay dividends?
AbSci does not currently pay dividends.
What is AbSci’s EPS estimate?
AbSci’s EPS estimate is -0.19.
How many shares outstanding does AbSci have?
AbSci has 171,614,010 shares outstanding.
What happened to AbSci’s price movement after its last earnings report?
AbSci reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.191. Following the earnings report the stock price went up 0.956%.
Which hedge fund is a major shareholder of AbSci?
Currently, no hedge funds are holding shares in ABSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbSci Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.63 (51.87% Upside)
$14.63 (51.87% Upside)
Blogger Sentiment
Neutral
ABSI Sentiment 57%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
117.78%
12-Months-Change
Fundamentals
Return on Equity
-59.21%
Trailing 12-Months
Asset Growth
28.12%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
AbSci
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
ABSI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive developments: encouraging interim Phase I safety and PK data for ABS-201, a meaningful strategic investment and collaboration with Eli Lilly, a substantial financing that materially strengthened the balance sheet (cash up ~60% quarter‑over‑quarter), clear near‑term clinical milestones, and notable platform efficiency gains (Atlas/Origin). Key risks and negatives are present but limited: efficacy is not yet unblinded, durability remains to be demonstrated beyond 26 weeks, operating expenses increased modestly (~10.2% R&D; ~8.2% SG&A), and successful commercialization depends on Absci's execution despite Lilly's involvement not conferring program rights. Overall, the highlights meaningfully outweigh the lowlights given the strong cash runway, strategic partner validation, and promising PK/safety profile, though clinical proof of efficacy and durability remain the critical upcoming catalysts.View all ABSI earnings summariesABSI Stock 12 Month Forecast
Average Price Target
$14.63
▲(51.87% Upside)
Technical Analysis
Autolus Therapeutics
―
―
ADC Therapeutics
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
6.02% Insiders
17.60% Mutual Funds
0.20% Other Institutional Investors
54.58% Public Companies and
Individual Investors